Short Interest in Advaxis, Inc. (OTCMKTS:ADXS) Drops By 27.5%
Short Interest in Advaxis, Inc. (OTCMKTS:ADXS) Drops By 27.5%
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 2,900 shares, a drop of 27.5% from the August 31st total of 4,000 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is currently 0.5 days.
Advaxis,Inc.(场外交易代码:ADXS-GET Rating)是空头股数9月份大幅下跌的目标。截至9月15日,空头股数共有2900股,与8月31日的4000股相比,下降了27.5%。以日均成交量6,000股计算,目前天数与回补比率为0.5天。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Separately, StockNews.com initiated coverage on Advaxis in a report on Monday, August 22nd. They set a "sell" rating for the company.
另外,StockNews.com在8月22日星期一的一份报告中启动了对Advaxis的报道。他们为该公司设定了“卖出”评级。
Advaxis Stock Performance
Advaxis股票表现
Advaxis stock traded down $0.04 during mid-day trading on Friday, hitting $2.16. 4,192 shares of the company's stock traded hands, compared to its average volume of 6,242. The company has a 50 day moving average of $3.20. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $44.80. The stock has a market capitalization of $3.92 million, a PE ratio of -21.60 and a beta of 2.07.
Advaxis股价在周五午盘交易中下跌0.04美元,触及2.16美元。该公司股票有4,192股易手,而其平均成交量为6,242股。该公司的50日移动均线切入位在3.20美元。Advaxis的52周低点为1.02美元,52周高位为44.80美元。该股市值392万美元,市盈率为-21.60倍,贝塔系数为2.07。
Advaxis Company Profile
Advaxis公司简介
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis,Inc.是一家临床阶段的生物技术公司,专注于在美国发现、开发和商业化专有的单核细胞增生性李斯特菌(LM)技术抗原递送产品。该公司正在开发ADXS-PSA,这是用于治疗转移性前列腺癌的第二阶段临床试验;ADXS-503,用于治疗非小细胞肺癌;以及ADXS-504,用于治疗前列腺癌。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Let Paychex Stock Work Hard For You
- 免费获取StockNews.com关于Advaxis的研究报告(ADXS)
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat:回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 雷神工业走出谷底
- 让Paychex股票为您努力工作
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Advaxis Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Advaxis和相关公司的最新新闻和分析师评级的每日简要摘要。